Action of novel copper compounds on the viability of Helicobacter pylori
Abstract number: P1243
Perna F., Hall T., Hickok S., Gant V., Vaira D., Holton J.
Objectives: Owing to the increasing prevalence of antibiotic resistance in H. pylori and the falling eradication rate, novel antimicrobial agents are being actively sought. One novel biocide is a series of highly reductive copper complexes that have broad antimicrobial activity. These compounds have no effect upon eukaryotic cell viability until an excess of 100ppm. Copper is also recognized as angiogenic and may have healing effects on ulcers. Therefore we have investigated the action of two of these compounds on the viability of Helicobacter pylori.
Methods: Cag A positive (NCTC11637); CagA negative (NCTC 12908 and ACTC J99) and 53 clinical isolates were tested. For 5 of the isolates a kill curve was performed with an inoculum of 1078 cfu/ml in sterile water at differing concentrations (0.5, 1.0, 5.0, and 12ppm) of two copper compounds CuAL42 and CuPC33 for 15, 30, 60 and 120 minutes. At each time point samples were withdrawn, decimal diluted into 1/4 strength Ringers lactate, plated and incubated. Subsequently all the isolates were tested at the same inoculum against 12 ppm for 60 and 120 mins. The plates were incubated for 5 days at 370 C in an atmosphere generated by CampyGen (Oxoid UK).
Results: CUAL42 was more active than CUPC33. At 5ppm the viable count was reduced by 56 logs at 2hrs whilst for CUAL42 at 1 hour and 2 hours respectively 20 and 40 isolates were completely killed compared to CUPC33, where 16 and 34 isolates were killed at 1 and 2 hours exposure. Neither Cag A status nor antibiotic sensitivity bore any relationship to the efficacy of the copper compounds.
Conclusions: These novel copper compounds deserve further study in relation to eradication of Helicobacter pylori
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|